response rates in depressed patients who were put on citalopram (Celexa) for eight weeks. Recently, some clinicians have advocated starting depressed patients with a combination of antidepressants, in the hopes that targeting multiple neurotransmitters will boost efficacy.
Read More
Most of us who prescribe benzodiazepines (BZs) have a love-hate relationship with them. On the one hand, they work quickly and effectively for anxiety and agitation, but on the other hand, we worry about sedative side effects and the fact that they can be difficult to taper because of withdrawal symptoms.
Read More
While psychotherapy remains the gold standard for treatment of post traumatic stress disorder, medications are often used to alleviate the symptoms of the illness.
Read More
Exposure and response prevention (ERP) is an extremely effective therapy. You can say with conviction that if a patient commits to this therapy, it really has a good chance of reducing suffering.
Read More
Some of the CBT techniques that have proven effective for panic disorder include breathing retraining, cognitive restructuring, and relaxation training.
Read More
Anxiety disorders are commonly seen in primary care, whether they present on their own, or comorbid with other illnesses. There’s good evidence for both cognitive-behavioral therapy (CBT) and pharmacotherapy in anxiety disorders, but many patients don’t receive such treatment.
Read More
Demonstrating the value of genetic testing in psychiatry is a tricky proposition. The latest case in point is the debate over whether determining variations in the gene coding for the serotonin transporter pump (5-HTTLPR) is useful for predicting future risk for depression.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
